Despite conflicting reports on NK cell activation, multiple EGFR-targeting TKIs consistently downregulate PD-L1 expression in NSCLC cells by inhibiting NF-κB and IL6 signaling [20,21]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.